To recover your password please fill in your email address
Please fill in below form to create an account with us
LUMOS2 is an innovative, precision oncology platform trial to address the unmet needs of people with relapsed Grade 2/3 IDH-mutant glioma. Allocation to LUMOS2 treatment arms will be guided by genomic profiling results. Participants with a matched, targeted therapy will be provided the therapy through a LUMOS2 targeted treatment arm and participants who do not have an actionable molecular target, will be randomly allocated to a LUMOS2 treatment arm with a novel mechanism of action. Each treatment arm will recruit 19 patients and the primary objective of the study is to determine progression-free survival at six months.
|
Trial Summary: |
LUMOS2 is an innovative, precision oncology platform trial to address the unmet needs of people with relapsed Grade 2/3 IDH-mutant glioma. Allocation to LUMOS2 treatment arms will be guided by genomic profiling results. Participants with a matched, targeted therapy will be provided the therapy through a LUMOS2 targeted treatment arm and participants who do not have an actionable molecular target, will be randomly allocated to a LUMOS2 treatment arm with a novel mechanism of action. Each treatment arm will recruit 19 patients and the primary objective of the study is to determine progression-free survival at six months. |
|
Supported by: |
Medical Research Future Fund, and Australian Brain Cancer Mission. |
|
Eligibility: |
Adults with histologically confirmed recurrent glioma, IDH-mutant, grade 2 or 3 after prior radiotherapy and alkylating chemotherapy. |
|
Registration ID: |
ACTRN12623000096651 |
|
Participation: |
Australia, Canada |
|
Australian Lead Group: |
COGNO |
|
Status: |
Recruiting |
|
Activation Date: |
31/8/2023 |
|
Chairs: |
Prof Hui Gan
|
|
Contact: |